<DOC>
	<DOCNO>NCT00058981</DOCNO>
	<brief_summary>Randomized , double-blind , parallel-group study evaluate safety efficacy multiple subcutaneous dos DiaPep277 patient Latent Autoimmune Diabetes Adults ( LADA ) . Study medication administer time 0 , 1 3 month , every 3 month total 8 administration . The total duration trial 24 month ( treatment 18 month follow-up additional 6 month ) . Patients male female age 30 65 year , inclusive , within 2 60 month diagnosis diabetes mellitus . Subjects must positive glutamic acid decarboxylate ( GAD ) autoantibody . At Screen Visit ( Visit 2 ) , subject ask discontinue use oral antidiabetic medication exception metformin . The subject place stable regimen insulin diet ( plus metformin need ) . Prior Baseline Visit ( Visit 3 ) , diabetic control must achieve diet insulin ( plus metformin need ) .</brief_summary>
	<brief_title>Safety , Tolerability , Immunological Clinical Efficacy Multiple Subcutaneous Doses DiaPep277 Latent Autoimmune Diabetes Adults ( LADA )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Inclusion Criteria Subjects meeting follow inclusion criterion screen consider admission study : The subject diagnosis diabetes mellitus accord WHO classification 2 month le 5 year enrollment . The subject 's diabetes control diet insulin ( plus metformin need ) 2 week ( 14 day ) prior Baseline Visit ( Visit 3 ) . The subject male female age 30 65 year . If female postmenopausal , subject pregnant use effective contraceptive method throughout study . The subject positive GAD autoantibody , define level great 99th percentile GAD antibody index normal control population laboratory ( e.g. , GAD antibody index equal 0.085 ) . The subject fasting Cpeptide level 0.30 nmol/L great 0.9 ng/mL time Screen Visit ( Visit 1 2 ) . Exclusion Criteria Subjects meeting follow exclusion criterion screen enrol study : The subject significant disease condition , include psychiatric disorder substance abuse , opinion site investigator , likely affect subject 's response treatment ability complete study . The subject history kind malignant tumor . The subject secondary diabetes mellitus . Within 2 week 14 day Baseline Visit randomize treatment , subject take oral antidiabetic medication metformin treat his/her diabetes . The subject clinical evidence diabetesrelated complication opinion site investigator would interfere subject 's participation and/or completion study . The subject history allergy asthma opinion site investigator would interfere subject 's participation completion study . The subject know immune deficiency disease , condition associate immune deficiency . The subject receive immunosuppressive immunomodulating agent cytotoxic therapy , medication , opinion site investigator , might interfere study . The subject pregnant woman woman plan become pregnant . The subject following : chronic hepatitis liver cirrhosis , chronic liver disease know test positive hepatitis B antigens hepatitis C antibodies abnormal liver function , define serum AST ALT 3 time upper limit normal The subject know suspected drug abuser . The subject influenzalike symptom day dose . The subject know test positive HIV antibody . The subject chronic hematologic disease . The subject impair renal function ( serum creatinine great 1.4 mg/dL ) . The subject severe ketonuria ( +++ urine stix test ; ++ repeat urine stix test ) . The subject BMI great 40kg/m2 . The subject hyperlipidemia ( fast serum triglyceride &gt; 1000 mg/dL ) . Suitable medical therapy treatment hyperlipidemia allow . The subject receive investigational drug within 3 month prior Visit 1 . The subject severe blood loss ( 400 mL , e.g. , blood donation ) within 2 month first dose study medication . The subject breastfeeding mother plan breastfeed .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>LADA</keyword>
	<keyword>latent autoimmune diabetes adult</keyword>
</DOC>